80,075 Shares in Inogen, Inc. (NASDAQ:INGN) Acquired by Sanctuary Advisors LLC

Sanctuary Advisors LLC purchased a new position in shares of Inogen, Inc. (NASDAQ:INGN - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 80,075 shares of the medical technology company's stock, valued at approximately $651,000. Sanctuary Advisors LLC owned approximately 0.34% of Inogen at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in INGN. Divisadero Street Capital Management LP boosted its holdings in shares of Inogen by 682.3% in the 2nd quarter. Divisadero Street Capital Management LP now owns 2,346,766 shares of the medical technology company's stock valued at $19,079,000 after purchasing an additional 2,046,766 shares in the last quarter. Brown Capital Management LLC boosted its holdings in shares of Inogen by 26.6% in the 1st quarter. Brown Capital Management LLC now owns 1,975,312 shares of the medical technology company's stock valued at $15,941,000 after purchasing an additional 414,903 shares in the last quarter. AQR Capital Management LLC boosted its holdings in shares of Inogen by 29.3% in the 2nd quarter. AQR Capital Management LLC now owns 570,994 shares of the medical technology company's stock valued at $4,642,000 after purchasing an additional 129,307 shares in the last quarter. Monaco Asset Management SAM acquired a new stake in shares of Inogen in the 2nd quarter valued at $610,000. Finally, Stokes Family Office LLC boosted its holdings in shares of Inogen by 162.1% in the 2nd quarter. Stokes Family Office LLC now owns 113,985 shares of the medical technology company's stock valued at $927,000 after purchasing an additional 70,500 shares in the last quarter. Institutional investors and hedge funds own 89.94% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on INGN. StockNews.com raised Inogen from a "sell" rating to a "hold" rating in a report on Tuesday, August 13th. Needham & Company LLC reissued a "hold" rating on shares of Inogen in a report on Wednesday, August 7th. One analyst has rated the stock with a sell rating, three have given a hold rating and one has assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of "Hold" and an average price target of $7.00.

Inogen Price Performance

Shares of NASDAQ INGN traded up $0.07 during mid-day trading on Tuesday, hitting $9.25. 192,222 shares of the stock traded hands, compared to its average volume of 347,918. Inogen, Inc. has a twelve month low of $4.13 and a twelve month high of $13.33. The company has a market cap of $218.09 million, a PE ratio of -2.21 and a beta of 1.04. The firm has a 50 day simple moving average of $11.04 and a two-hundred day simple moving average of $9.13.

Inogen (NASDAQ:INGN - Get Free Report) last announced its earnings results on Tuesday, August 6th. The medical technology company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.55) by $0.31. The firm had revenue of $88.77 million for the quarter, compared to the consensus estimate of $82.50 million. Inogen had a negative return on equity of 45.37% and a negative net margin of 28.30%. The business's quarterly revenue was up 6.1% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.42) EPS. On average, equities research analysts anticipate that Inogen, Inc. will post -1.92 earnings per share for the current fiscal year.

Inogen Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.